1. Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Japan;
2. Division of Molecular Therapy, The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan;
3. Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan;
4. Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan;
5. Division of Hematology-Oncology, Japanese Red Cross Society Narita Hospital, Narita, Japan;
6. Department of Transfusion Medicine, Tokyo Metropolitan Tama Medical Center, Tama, Japan;
7. Department of Hematology, Osaka City University Hospital, Osaka, Japan;
8. Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan;
9. Department of Hematology, Chiba University Hospital, Chiba, Japan;
10. Department of Hematology, Nippon Medical School Hospital, Tokyo, Japan;
11. Department of Hematology and Oncology, Children's Medical Center, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan;
12. Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan;
13. Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, Japan; and
14. Department of Internal Medicine Division of Hematology, Aichi Medical University, Nagakute, Japan